Shin Chan-young, Professor of Pharmacology, Konkuk University Graduate School of Medicine, presented at the Society of Applied Pharmacology Conference 

[2015 Spring Conference of Korean Society of Applied Pharmacy]

It has been suggested that attention should be paid to agmatine as a new drug candidate for the treatment of hyperactivity disorder (ADHD).

Professor Shin Chan-young of the Department of Pharmacology at Konkuk University Graduate School introduced ADHD risk factors and new targets for treatment at the Spring Conference of the Korean Society of Applied Pharmacy held at the New Millennium Hall of Konkuk University.

Professor Shin said, "Agmatine can have a therapeutic effect," and added, "It is already used as a dry season meal, and it shows potential as a target for treating ASD behavior, whether used directly or by controlling the enzyme system."

Agmatine is a kind of amine produced by decarboxylation of arginine and refers to an intermediate in polyamine biosynthesis of bacteria or plants.

Professor Mi-ryung Song (GIST) and Professor Hyuk-wan Ko (Dongguk University) also presented the latest research findings on ADHD treatment through their respective presentations.

Seoul National University Professor Kim Boong-nyeon gave the theme of 'Genetic and Environmental Effects on the Pathophysiology of Attention Deficit Hyperactivity Disorder (ADHD)', and Johns Hopkins University Professor Joseph P. ', suggesting the direction for new drugs for brain development disorders.

The conference was held under the theme of 'Development of New Drugs for the Treatment of Neurodevelopmental Disorders: Opportunities and Challenges from a Practical Perspective'.

It focuses on sharing clinical and up-to-date research findings and new drug discovery strategies for the treatment of neurodevelopmental disorders.

In his opening remarks, Jaehoon Jung, president of the Society for Applied Pharmacy, said, "I hope this will be a place to share the experiences of researchers who can access the latest trends, major targets, and key points for new drug creation for the treatment of neurodevelopmental disorders such as ADHD, autism, and Tourette's syndrome." .

Reporter Kim Hyun-joo hyunjuk90@gmail.com